SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bujak JS, Aptekar RG, Decker JL, Wolff SM. Juvenile rheumatoid arthritis presenting in the adult as fever of unknown origin. Medicine (Baltimore) 1973; 52: 43144.
  • 2
    Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19: 42430.
  • 3
    Fautrel B, Borget C, Rozenberg S, Meyer O, le Loet X, Masson C, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 1999; 26: 3738.
  • 4
    Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991; 70: 11836.
  • 5
    Schifter T, Lewinski UH. Adult onset Still's disease associated with Epstein-Barr virus infection in a 66-year-old woman. Scand J Rheumatol 1998; 27: 45860.
  • 6
    Daibata M, Taguchi H. Human herpesvirus 6 and adult-onset Still's disease [letter]. Am J Med 2002; 113: 532.
  • 7
    Newkirk MM, Lemmo A, Commerford K, Esdaile JM, Brandwein S. Aberrant cellular localization of rubella viral genome in patients with adult Still's disease: a pilot study. Autoimmunity 1993; 16: 3943.
  • 8
    Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome) [review]. JAMA 1992; 268: 34525.
  • 9
    Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 2003; 30: 24227.
  • 10
    Caramaschi P, Biasi D, Carletto A, Bambara LM. A case of adult onset Still's disease treated with infliximab [letter]. Clin Exp Rheumatol 2002; 20: 113.
  • 11
    Olivieri I, de Stefano G, Padula A, la Gala A, de Stefano C. Infliximab in a case of early adult-onset Still's disease [letter]. Clin Rheumatol 2003; 22: 36970.
  • 12
    Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 2001; 60 Suppl 3: iii557.
  • 13
    Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002; 132: 41422.
  • 14
    Kokkinos A, Iliopoulos A, Greka P, Efthymiou A, Katsilambros N, Sfikakis PP. Successful treatment of refractory adult-onset Still's disease with infliximab: a prospective, non-comparative series of four patients. Clin Rheumatol 2004; 23: 459.
  • 15
    Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 2001; 19: 32932.
  • 16
    Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β. Proc Natl Acad Sci U S A 2001; 98: 28716.
  • 17
    Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, et al. The precursor form of IL-1α is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A 2004; 101: 24349.
  • 18
    Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 2001; 14: 33442.
  • 19
    Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS) [review]. Autoimmun Rev 2004; 3: 6975.
  • 20
    Maeno N, Takei S, Imanaka H, Yamamoto K, Kuriwaki K, Kawano Y, et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum 2004; 50: 19358.
  • 21
    Bywaters EG. Still's disease in the adult. Ann Rheum Dis 1971; 30: 12133.
  • 22
    Larson EB. Adult Still's disease: evolution of a clinical syndrome and diagnosis, treatment, and follow-up of 17 patients. Medicine (Baltimore) 1984; 63: 8291.
  • 23
    Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002; 46: 11716.
  • 24
    Tamesis ER, Reginato AM, Hubscher O, Reginato AJ. Etanercept in recalcitrant adult onset Still's disease (AOSD) [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S229.
  • 25
    Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30: 16245.
  • 26
    Haraoui B, Bourrelle D, Kaminska E. Anakinra in the treatment of adult onset Still's disease [abstract]. Ann Rheum Dis 2004; 63 Suppl 1: 263.
  • 27
    Aelion JA, Odhav SK. Prompt response to treatment with anakinra in adult onset Still's disease [abstract]. Ann Rheum Dis 2004; 63 Suppl 1: 265.
  • 28
    Netea MG, Radstaske T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: association with decreased interferon-γ production and Toll-like receptor 4 expression. Arthritis Rheum 2003; 48: 18537.
  • 29
    Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 143350.
  • 30
    Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170: 162733.
  • 31
    Simon A, Bodar EJ, van der Hilst JC, van der Meer JW, Fiselier TJ, Cuppen MP, et al. Beneficial response to interleukin-1 receptor antagonist in TRAPS [letter]. Am J Med 2004; 117: 20810.
  • 32
    Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 1988; 62: 246771.
  • 33
    Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-α in cancer patients. J Clin Oncol 1988; 6: 132834.
  • 34
    Brown TD, Goodman P, Fleming T, Macdonald JS, Hersh EM, Braun TJ. A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. J Immunother 1991; 10: 3768.
  • 35
    Budd GT, Green S, Baker LH, Hersh EP, Weick JK, Osborne CK. A Southwest Oncology Group phase II trial of recombinant tumor necrosis factor in metastatic breast cancer [published erratum appears in Cancer 1992;69:2866]. Cancer 1991; 68: 16945.
  • 36
    Ogilvie AC, Hack CE, Wagstaff J, van Mierlo GJ, Erenberg AJ, Thomsen LL, et al. IL-1β does not cause neutrophil degranulation but does lead to IL- 6, IL-8, and nitrite/nitrate release when used in patients with cancer. J Immunol 1996; 156: 38994.
  • 37
    Smith JW, Longo DL, Alford WG, Janik JE, Sharfman WH, Gause BL, et al. The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin. N Engl J Med 1993; 328: 75661.
  • 38
    Smith JW, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, et al. The toxic and hematologic effects of interleukin-1α administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 10: 114152.
  • 39
    Crown J, Jakubowski A, Kemeny N, Gordon M, Gasparetto C, Wong G, et al. A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 1991; 78: 14207.
  • 40
    Crown J, Jakubowski A, Gabrilove J. Interleukin-1: biological effects in human hematopoiesis [review]. Leuk Lymphoma 1993; 9: 43340.
  • 41
    Laughlin MJ, Kirkpatrick G, Sabiston N, Peters W, Kurtzberg J. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony stimulating factors: G-CSF, GM-CSF, IL-1, IL-2 and M-CSF. Ann Hematol 1993; 67: 26776.
  • 42
    Nemunaitis J, Ross M, Meisenberg B, O'Reilly R, Lilleby K, Buckner CD, et al. Phase I study of recombinant human interleukin-1β (rhIL-1β) in patients with bone marrow failure. Bone Marrow Transplant 1994; 14: 5838.
  • 43
    Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004; 25: 94102.
  • 44
    Di Iorio A, Ferrucci L, Sparvieri E, Cherubini A, Volpato S, Corsi A, et al, and the InCHIANTI study. Serum IL-1β levels in health and disease: a population-based study. Cytokine 2003; 22: 198205.
  • 45
    Moore MA. Role of interleukin-1 in hematopoiesis [review]. Immunol Res 1989; 8: 16575.
  • 46
    Dinarello CA. Biologic basis for interleukin-1 in disease [review]. Blood 1996; 87: 2095147.
  • 47
    Van der Poll T, van Deventer SJ, Hack CE, Wolbink GJ, Aarden LA, Buller HR, et al. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992; 79: 6938.
  • 48
    Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E III, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988; 6: 34450.
  • 49
    Imrie KR, Sheridan B, Colwill R, Crump M, Stewart AK, McCrae J, et al. A phase I study of interleukin-6 after autologous bone marrow transplantation for patients with poor prognosis Hodgkin's disease. Leuk Lymphoma 1997; 25: 55563.
  • 50
    Lazarus HM, Winton EF, Williams SF, Grinblatt D, Campion M, Cooper BW, et al. Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer. Bone Marrow Transplant 1995; 15: 93542.
  • 51
    Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999; 163: 15218.
  • 52
    Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22: 1221.
  • 53
    Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994; 13: 118996.
  • 54
    Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994; 180: 124350.
  • 55
    Zheng H, Fletcher D, Kozak W, Jiang M, Hofmann KJ, Conn CA, et al. Resistance to fever induction and impaired acute-phase response in interleukin-1β-deficient mice. Immunity 1995; 3: 919.
  • 56
    Fantuzzi G, Sacco S, Ghezzi P, Dinarello CA. Physiological and cytokine responses in interleukin-1β-deficient mice after zymosan-induced inflammation. Am J Physiol 1997; 273: R4006.
  • 57
    Kozak W, Kluger MJ, Soszynski D, Conn CA, Rudolph K, Leon LR, et al. IL-6 and IL-1β in fever: studies using cytokine-deficient (knockout) mice. Ann N Y Acad Sci 1998; 856: 3347.
  • 58
    Chai Z, Gatti S, Toniatti C, Poli V, Bartfai T. Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1β: a study on IL-6-deficient mice. J Exp Med 1996; 183: 3116.
  • 59
    Li S, Goorha S, Ballou LR, Blatteis CM. Intracerebroventricular interleukin-6, macrophage inflammatory protein-1β and IL-18: pyrogenic and PGE2-mediated? Brain Res 2003; 992: 7684.
  • 60
    Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 3015.
  • 61
    Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364: 177985.
  • 62
    Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 31925.
  • 63
    Lovell DJ, Bowyer SL. Treatment of neonatal onset multisystem inflammatory disease (NOMID) with IL-1Ra (anakinra) [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S517.
  • 64
    Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome [letter]. N Engl J Med 2003; 348: 25834.
  • 65
    Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 60712.
  • 66
    Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46: 33408.
  • 67
    Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti–interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002; 46: 33889.
  • 68
    Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001; 44: 55060.
  • 69
    Sugiura T, Kawaguchi Y, Harigai M, Terajima-Ichida H, Kitamura Y, Furuya T, et al. Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun 2002; 3: 3949.
  • 70
    Siegel J. FDA briefing document on safety and efficacy update on approved TNF-blocking agents. URL: www.FDA.gov/ohrms/dockets/ac/03.
  • 71
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α-neutralizing agent. N Engl J Med 2001; 345: 1098104.
  • 72
    Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 12615.
  • 73
    Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al, for the 990757 Study Group. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48: 92734.